Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Enhancement of antimycotic activity of amphotericin B by targeting the oxidative stress response of Candida and cryptococcus with natural dihydroxybenzaldehydes.

Kim JH, Faria NC, Martins Mde L, Chan KL, Campbell BC.

Front Microbiol. 2012 Jul 19;3:261. doi: 10.3389/fmicb.2012.00261. eCollection 2012.

2.

Targeting the mitochondrial respiratory chain of Cryptococcus through antifungal chemosensitization: a model for control of non-fermentative pathogens.

Kim JH, Haff RP, Faria NC, Martins Mde L, Chan KL, Campbell BC.

Molecules. 2013 Jul 25;18(8):8873-94. doi: 10.3390/molecules18088873.

3.

Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus.

Faria NC, Kim JH, Gonçalves LA, Martins Mde L, Chan KL, Campbell BC.

Lett Appl Microbiol. 2011 May;52(5):506-13. doi: 10.1111/j.1472-765X.2011.03032.x. Epub 2011 Mar 14.

4.

Antifungal activity of redox-active benzaldehydes that target cellular antioxidation.

Kim JH, Chan KL, Mahoney N, Campbell BC.

Ann Clin Microbiol Antimicrob. 2011 May 31;10:23. doi: 10.1186/1476-0711-10-23.

5.

Targeting the oxidative stress response system of fungi with redox-potent chemosensitizing agents.

Kim JH, Chan KL, Faria NC, Martins Mde L, Campbell BC.

Front Microbiol. 2012 Mar 16;3:88. doi: 10.3389/fmicb.2012.00088. eCollection 2012.

6.

The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.

Mesa-Arango AC, Trevijano-Contador N, Román E, Sánchez-Fresneda R, Casas C, Herrero E, Argüelles JC, Pla J, Cuenca-Estrella M, Zaragoza O.

Antimicrob Agents Chemother. 2014 Nov;58(11):6627-38. doi: 10.1128/AAC.03570-14. Epub 2014 Aug 25.

7.

Enhancement effect of N-methyl-N″-dodecylguanidine on the vacuole-targeting fungicidal activity of amphotericin B against the pathogenic fungus Candida albicans.

Yutani M, Ogita A, Usuki Y, Fujita K, Tanaka T.

J Antibiot (Tokyo). 2011 Jul;64(7):469-74. doi: 10.1038/ja.2011.31. Epub 2011 Apr 27. Erratum in: J Antibiot (Tokyo). 2011 Nov;64(11):757.

PMID:
21522157
8.
9.

Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole.

Carrillo-Muñoz AJ, Quindós G, Tur C, Ruesga M, Alonso R, del Valle O, Rodriguez V, Arévalo MP, Salgado J, Martin-Mazuelos E, Bornay-Llinares FJ, del Palacio A, Cuétara M, Gasser I, Hernández-Molina JM, Pemán J.

Chemotherapy. 2000 Jul-Aug;46(4):235-44.

PMID:
10859429
10.

Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?

Kovacicova G, Krupova Y, Lovaszova M, Roidova A, Trupl J, Liskova A, Hanzen J, Milosovic P, Lamosova M, Macekova L, Szovenyiova Z, Purgelova A, Obertik T, Bille J, Krcmery V.

J Infect Chemother. 2000 Dec;6(4):216-21.

PMID:
11810569
11.
12.

Influence of fungicidal activity against Candida tropicalis on the efficacy of micafungin and liposomal amphotericin B in a neutropenic murine lethal infection model.

Takemoto K, Nakayama T, Kanazawa K, Ueda Y.

Pharmacology. 2012;90(3-4):133-45. doi: 10.1159/000341370. Epub 2012 Jul 26.

PMID:
22847175
13.

Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.

Matthews RC, Rigg G, Hodgetts S, Carter T, Chapman C, Gregory C, Illidge C, Burnie J.

Antimicrob Agents Chemother. 2003 Jul;47(7):2208-16.

14.

The vacuole-targeting fungicidal activity of amphotericin B against the pathogenic fungus Candida albicans and its enhancement by allicin.

Borjihan H, Ogita A, Fujita K, Hirasawa E, Tanaka T.

J Antibiot (Tokyo). 2009 Dec;62(12):691-7. doi: 10.1038/ja.2009.103. Epub 2009 Oct 30.

PMID:
19876074
15.

Enhancement of amphotericin B activity against Candida albicans by superoxide radical.

Okamoto Y, Aoki S, Mataga I.

Mycopathologia. 2004 Jul;158(1):9-15.

PMID:
15487314
16.

Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.

Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, Yan JJ, Yu KW, Wu JJ, Ko WC, Yang YC, Liu YC, Teng LJ, Liu CY, Luh KT.

Antimicrob Agents Chemother. 2005 Feb;49(2):512-7.

17.

Stable phenotypic resistance of Candida species to amphotericin B conferred by preexposure to subinhibitory levels of azoles.

Vazquez JA, Arganoza MT, Boikov D, Yoon S, Sobel JD, Akins RA.

J Clin Microbiol. 1998 Sep;36(9):2690-5.

18.

[In vitro synergistic effect of moxifloxacin and amphotericin B combination against Candida strains].

Yalçin B, Kalkanci A, Gürelik F, Fidan I, Kustimur S, Ozdek S.

Mikrobiyol Bul. 2010 Jan;44(1):65-70. Turkish.

PMID:
20455400
19.

In vitro antifungal activity of phenothiazines and their combination with amphotericin B against different Candida species.

Galgóczy L, Bácsi A, Homa M, Virágh M, Papp T, Vágvölgyi C.

Mycoses. 2011 Nov;54(6):e737-43. doi: 10.1111/j.1439-0507.2010.02010.x. Epub 2011 May 23.

PMID:
21605196
20.

Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B.

Oda MN, Hargreaves PL, Beckstead JA, Redmond KA, van Antwerpen R, Ryan RO.

J Lipid Res. 2006 Feb;47(2):260-7. Epub 2005 Nov 28.

Supplemental Content

Support Center